Healx, the AI-powered and patient-inspired tech company specialising in treatments for rare diseases, has opened applications to its new Rare Treatment Accelerator (RTA).
The programme focuses on finding new treatments for rare diseases by partnering with selected rare disease patient groups to leverage the significantly accelerated process of drug repurposing, thanks to Healx’s AI platform.
Healx intends to invest up to the value of $1 million in AI and drug discovery resources per disease project, out of the total budget of $20 million.
The initiative will be led by Dr Bruce Bloom, who joins as Chief Collaboration Officer, bringing a wealth of experience in drug repurposing with over a dozen therapies re-channelled to rare disease patients as founder and CEO of the charity Cures Within Reach.
Dr Bloom will be responsible for overseeing Healx’s existing collaborations and seeking out new global partnership opportunities with a wide range of organisations, including rare disease patient groups, research institutions, investigators and clinical groups.
Applications are now open for Healx’s RTA programme, which was launched last month alongside the closing of its $56 million Series B financing.
In total, Healx has committed $20 million, over the next two years, for investing in partnerships through the RTA, with no financial contribution required from patient groups.